Prevalence of Helicobacter pylori in gastrointestinal disorders and concentrations of ciprofloxacin in serum and gastric mucosa.
Endoscopic antral biopsies were obtained from 30 patients with several gastrointestinal disorders and analysed for the presence of H. pylori. This bacterium was present in 80% and 58%, respectively, of patients with either gastric and duodenal ulcers and gastric neoplasm. In none of the healthy individuals, H. pylori could be found. Another 14 patients with various diseases of the stomach, undergoing a major gastric resection, had been treated with 200 mg ciprofloxacin intravenously immediately before the operation. Blood and various tissues samples were taken during the operation. The prevalence of IgG antibodies against H. pylori in these patients was 93%. H. pylori could be determined in 71% of the cases by the urease production; by culture, this was possible in only one case. The mean peak concentration of ciprofloxacin in serum was 5.31 mg/l and 1.17 mg/l, respectively, immediately and 60 min after the end of infusion; in tissues of antrum and duodenum, 1.59 to 1.64 mg/kg and 1.41 to 1.72 mg/kg, respectively, 45-270 min after the infusion. The results show that ciprofloxacin rapidly penetrates into tissues and attains concentrations greater than the MIC90 for H. pylori. However, these concentrations can inhibit the isolation of this microorganism but not its urease activity. This fact could be interpreted by the existence of a nonculturable but metabolically active form of H. pylori. This would explain the high rate of recrudescence following most types of currently applied therapeutic schemes.
Krausse
R
R
Institute for Medical Microbiology and Virology, Dept. of Surgery, University of Kiel, Germany.
Lorentzen
T
T
Erttmann
M
M
Ullmann
U
U
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002939:Ciprofloxacin / Q000097:blood / Q000493:pharmacokinetics* / Q000627:therapeutic use; D005260:Female; D005753:Gastric Mucosa / Q000378:metabolism*; D005767:Gastrointestinal Diseases / Q000188:drug therapy / Q000378:metabolism / Q000382:microbiology*; D016481:Helicobacter Infections / Q000150:complications / Q000453:epidemiology*; D016480:Helicobacter pylori / Q000187:drug effects / Q000302:isolation & purification*; D006801:Humans; D008297:Male; D008875:Middle Aged; D015995:Prevalence; D013274:Stomach Neoplasms / Q000382:microbiology
D002939:Ciprofloxacin